CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. It also provides related health services. The company offers OTC products, including cold, skin, gastrointestinal, cough relieving, orthopedics, and pediatrics drugs; prescription drug products in traditional Chinese medicine, tumors, cardiovascular and cerebrovascular, digestive system, orthopedics, and pediatrics; Chinese medicine injections; formula granules; and anti-infective drugs. It sells its products under 999 family medicine brands, Sanjiuweitai series, 999 Ganmaoling series, 999 dermatitis series, and other products. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, the People's Republic of China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources (Holdings) Co., Ltd.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

颈复康药业集团有限公司 manufactures and sells pharmaceutical products, including granules, capsules, and other forms. The company describes itself as catering to various health needs.

颈复康药业集团有限公司

哈药集团人民同泰医药股份有限公司 is a well-known pharmaceutical distribution company in China, primarily engaged in the retail and wholesale of pharmaceuticals, online pharmacy, and specialized hospitals.

哈药集团人民同泰医药股份有限公司

CanSinoBIO is a biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & development, manufacturing and commercialization of vaccine products for human use.

康希诺生物

Tianjin CanSino Biotechnology Inc. | 624 followers on LinkedIn. Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

CanSino has established bacterial and cell/viral culture pilot facilities in compliance to the current GMP standard.

Metric
Company Name	CanSino Biologics Inc.	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	颈复康药业集团有限公司	哈药集团人民同泰医药股份有限公司
Symbol	6.18K	999
MSH ID	COM:CANSINOTECH	CN:COM:999	CN:COM:CDJFK	CN:COM:HYRMTT
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - Specialty & Generic	Pharmaceuticals	Pharmaceuticals
Country	CN	CN	CN	CN
Stage
Employee Count	1.49K	20.32K
Website	cansinotech.com	999.com.cn	cdjfk.com.cn	hyrmtt.com.cn
LinkedIn	cansino-biotechnology-inc.		%E9%A2%88%E5%A4%8D%E5%BA%B7%E8%8D%AF%E4%B8%9A%E9%9B%86%E5%9B%A2%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
Founders

Metric
Market Cap	833.96M	7.27B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	49.12M	3.36B
Revenue (LTM)
Revenue (NTM)
Gross Profit	-61.04M	1.73B
EBITDA	-203.86M	602.14M
Operating Income	-236.92M	484.72M
Net Income	-203.94M	392.41M
EPS	-0.83	0.40
Diluted EPS	-0.83	0.40
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.14	0.53
Operating Profit Margin	-0.86	0.16
EBITDA Margin	-4.15	0.18
Net Profit Margin	-1.42	0.13
Return on Equity	-0.16	0.17
Return on Assets	-0.11	0.08
Return on Capital Employed	-0.08	0.15

6185

COM:CANSINOTECH

康希诺生物

Last Close

26.95

25/11 08:08

Market Cap

6.49B

Beta: -

Volume Today

1.41M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		19.26
P/B Ratio		3.02
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	20.35	2.60
EV Multiple	-3.00	15.32

Metric
Days Sales Outstanding	485.87	127.05
Days Payables Outstanding	170.20	92.05
Days Inventory Outstanding	251.49	151.91
Operating Cycle	815.83	278.23
Cash Conversion Cycle	770.86	205.87
Asset Turnover	0.07	0.64

Metric
Operating Cash Flow	-124.92M	580.50M
Free Cash Flow	-208.89M	462.59M
Cash Flow to Debt	-0.12	1.51
Operating Cash Flow/Sales	-0.43	0.19
Free Cash Flow Yield	-0.25	0.06

Metric
Cash & Equivalents	388.10M	873.89M
Accounts Receivable	36.58M	87.16M
Inventory	48.53M	703.20M
Goodwill		704.78M
Debt to Capitalization	0.34	0.16
Debt to Assets	0.21	0.08
Current Ratio	2.24	1.77
Quick Ratio	2.22	1.48

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	1.04	0.03
SG&A to Revenue	0.34	0.03